|
Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Clinical research trials and Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer. Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer clinical trial. Subjects frequently obtain the most expert healthcare possible for their Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer  Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
For Condition: stage 4 squamous cell carcinoma of the lip and oral cavity,stage 4B squamous cell carcinoma of the nasopharynx,metastatic squamous neck cancer with occult primary squamous cell carcinoma,recurrent squamous cell carcinoma of the nasopharynx,recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity,stage 5C squamous cell carcinoma of the nasopharynx,stage 4A squamous cell carcinoma of the nasopharynx,recurrent squamous cell carcinoma of the lip and oral cavity,stage 4 squamous cell carcinoma of the hypopharynx,stage 4 squamous cell carcinoma of the paranasal sinus and nasal cavity,recurrent squamous cell carcinoma of the hypopharynx,recurrent squamous cell carcinoma of the larynx,stage 4 squamous cell carcinoma of the oropharynx,recurrent metastatic squamous neck cancer with occult primary,recurrent squamous cell carcinoma of the oropharynx,stage 4 squamous cell carcinoma of the larynx
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Southwest Oncology Group
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of docetaxel plus carboplatin in treating patients who have metastatic or recurrent head and neck cancer.
Details: OBJECTIVES: I. Assess the survival of patients with metastatic or recurrent squamous cell carcinoma of the head and neck receiving docetaxel and carboplatin. II. Assess time to treatment failure and response rate (unconfirmed and confirmed complete and partial response) in this patient population. III. Evaluate the toxicities of this regimen in this patient population. PROTOCOL OUTLINE: Patients receive docetaxel IV over 1 hour immediately followed by carboplatin IV over 30 minutes on day 1. Courses repeat every 3 weeks in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 1 year, every 6 months for 2 years, then annually thereafter until death. PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study over 18 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically proven squamous cell carcinoma of the head and neck; Metastatic disease at diagnosis OR Persistent, metastatic or recurrent disease following surgery and/or radiotherapy - No newly diagnosed nonmetastatic disease - Bidimensionally measurable disease; Demonstrated progressive disease if only measurable site is within a previous radiotherapy port --Prior/Concurrent Therapy-- - Biologic therapy: No concurrent biologic therapy - Chemotherapy: No prior carboplatin or cisplatin; No prior chemotherapy for recurrent disease; No other concurrent chemotherapy - Endocrine therapy: No concurrent hormonal therapy (except oral contraceptives or treatment for osteoporosis) - Radiotherapy: See Disease Characteristics; At least 28 days since prior radiotherapy and recovered; No concurrent radiotherapy - Surgery: See Disease Characteristics; At least 28 days since prior surgery and recovered --Patient Characteristics-- - Age: 18 and over - Performance status: SWOG 0-2 - Life expectancy: Not specified - Hematopoietic: WBC at least 3,000/mm3 OR Absolute neutrophil count at least 1,500/mm3; Platelet count at least 100,000/mm3 - Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN); SGOT or SGPT no greater than 1.5 times ULN; Alkaline phosphatase no greater than 2.5 times ULN - Renal: Calcium no greater than upper limit of normal (ULN); Creatinine no greater than 1.5 times ULN OR Creatinine clearance at least 60 mL/min - Other: Not pregnant or nursing; Fertile patients must use effective contraception; No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or any adequately treated stage I or II cancer that is currently in complete remission; No neuropathy sensory greater than grade 1; No history of hypersensitivity reaction to Polysorbate 80
Total Enrollment:
Location and Contact Information:
Overall Study Official:
WolframSamlowski, Study Chair, Southwest Oncology Group
Veterans Affairs Medical Center - New Orleans
New Orleans, Louisiana, 70112
United States
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033-0800
United States
University of Texas Medical Branch
Galveston, Texas, 77555-1329
United States
MBCCOP - University of New Mexico HSC
Albuquerque, New Mexico, 87131
United States
University of Colorado Cancer Center
Denver, Colorado, 80262
United States
Veterans Affairs Medical Center - Seattle
Seattle, Washington, 98108
United States
Henry Ford Hospital
Detroit, Michigan, 48202
United States
CCOP - Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, 49503
United States
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, 73104
United States
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
United States
University of Kansas Medical Center
Kansas City, Kansas, 66160-7357
United States
Veterans Affairs Medical Center - Phoenix (Hayden)
Phoenix, Arizona, 85012
United States
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
Hines, Illinois, 60141
United States
Tulane University School of Medicine
New Orleans, Louisiana, 70112
United States
CCOP - Virginia Mason Research Center
Seattle, Washington, 98101
United States
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65807
United States
CCOP - St. Louis-Cape Girardeau
St. Louis, Missouri, 63141
United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
United States
Keesler Medical Center - Keesler AFB
Keesler AFB, Mississippi, 39534-2576
United States
Cancer Services
Columbus, Ohio, 43214
United States
Veterans Affairs Medical Center - Jackson
Jackson, Mississippi, 39216
United States
CCOP - Columbus
Columbus, Ohio, 43206
United States
Dwight David Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905-5650
United States
CCOP - Wichita
Wichita, Kansas, 67214-3882
United States
Veterans Affairs Medical Center - Boston (Jamaica Plain)
Jamaica Plain, Massachusetts, 02130
United States
St. Louis University Health Sciences Center
St. Louis, Missouri, 63110-0250
United States
Veterans Affairs Medical Center - Wichita
Wichita, Kansas, 67218
United States
Cleveland Clinic Cancer Center
Cleveland, Ohio, 44195
United States
MBCCOP - University of South Alabama
Mobile, Alabama, 36688
United States
Veterans Affairs Medical Center - Temple
Temple, Texas, 76504
United States
University of California Davis Medical Center
Sacramento, California, 95817
United States
Veterans Affairs Medical Center - Albuquerque
Albuquerque, New Mexico, 87108-5138
United States
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
United States
Texas Tech University Health Science Center
Lubbock, Texas, 79423
United States
Barrett Cancer Center, The University Hospital
Cincinnati, Ohio, 45219
United States
CCOP - Dayton
Kettering, Ohio, 45429
United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78284-7811
United States
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403
United States
Veterans Affairs Medical Center - Detroit
Detroit, Michigan, 48201-1932
United States
CCOP - Kansas City
Kansas City, Missouri, 64131
United States
Veterans Affairs Outpatient Clinic - Martinez
Martinez, California, 94553
United States
CCOP - Greenville
Greenville, South Carolina, 29615
United States
Herbert Irving Comprehensive Cancer Center
New York City, New York, 10032
United States
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
United States
Huntsman Cancer Institute
Salt Lake City, Utah, 84132
United States
Loyola University Medical Center
Maywood, Illinois, 60153
United States
Veterans Affairs Medical Center - Salt Lake City
Salt Lake City, Utah, 84148
United States
MBCCOP - LSU Medical Center
New Orleans, Louisiana, 70112
United States
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
United States
Veterans Affairs Medical Center - Denver
Denver, Colorado, 80220
United States
Arizona Cancer Center
Tucson, Arizona, 85724
United States
Veterans Affairs Medical Center - Long Beach
Long Beach, California, 90822
United States
Veterans Affairs Medical Center - Little Rock (McClellan)
Little Rock, Arkansas, 72205
United States
Providence Hospital - Southfield
Southfield, Michigan, 48075-9975
United States
Veterans Affairs Medical Center - Biloxi
Biloxi, Mississippi, 39531-2410
United States
Veterans Affairs Medical Center - San Antonio (Murphy)
San Antonio, Texas, 78284
United States
CCOP - Scott and White Hospital
Temple, Texas, 76508
United States
CCOP - Central Illinois
Decatur, Illinois, 62526
United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201
United States
Simmons Cancer Center - Dallas
Dallas, Texas, 75235-9154
United States
Swedish Cancer Institute
Seattle, Washington, 98104
United States
CCOP - Greater Phoenix
Phoenix, Arizona, 85006-2726
United States
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
United States
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
United States
Veterans Affairs Medical Center - Tucson
Tucson, Arizona, 85723
United States
Boston Medical Center
Boston, Massachusetts, 02118
United States
Veterans Affairs Medical Center - Portland
Portland, Oregon, 97207
United States
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
United States
CCOP - Northwest
Tacoma, Washington, 98405-0986
United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752
United States
Veterans Affairs Medical Center - Lexington
Lexington, Kentucky, 40511-1093
United States
Chao Family Comprehensive Cancer Center
Orange, California, 92868
United States
CCOP - Columbia River Program
Portland, Oregon, 97213
United States
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813
United States
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
United States
Veterans Affairs Medical Center - Oklahoma City
Oklahoma City, Oklahoma, 73104
United States
Veterans Affairs Medical Center - Cincinnati
Cincinnati, Ohio, 45220-2288
United States
Veterans Affairs Medical Center - Kansas City
Kansas City, Missouri, 64128
United States
David Grant Medical Center
Travis Air Force Base, California, 94535
United States
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
United States
Beckman Research Institute, City of Hope
Los Angeles, California, 91010
United States
Oregon Cancer Center at Oregon Health Sciences University
Portland, Oregon, 97201-3098
United States
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
United States
Veterans Affairs Medical Center - Shreveport
Shreveport, Louisiana, 71130
United States
Louisiana State University Health Sciences Center - Shreveport
Shreveport, Louisiana, 71130-3932
United States
Additional Information:
Study ID Numbers: CDR0000067086; SWOG-S9902
Study Start Date: November 1999
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00003908
Other Stage 4 Squamous Cell Carcinoma Of The Lip And Oral Cavity Studies:
1. Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Related Studies:
Other stage 4 squamous cell carcinoma of the lip and oral cavity Clinical Trials
Other Alabama Clinical Trials
Other Mobile Clinical Trials
Docetaxel Plus Carboplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
|
|
|
|
|
|
|
|
